aldosterone has been researched along with Breast Neoplasms in 42 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To elucidate the combined effects of fadrozole (nonsteroidal aromatase inhibitor) and tamoxifen, 11 postmenopausal patients with recurrent breast cancer were examined between October 1996 and June 1998." | 9.09 | [A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen]. ( Kimura, M; Nomura, Y; Ohashi, Y; Takashima, S; Toge, T; Tominaga, T, 2000) |
| "This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels." | 9.08 | Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995) |
| "Aminoglutethimide (Ag) is a potent aromatase-enzyme inhibitor used in the treatment of patients with breast cancer." | 9.07 | Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. ( Carella, MJ; Dimitrov, NV; Gossain, VV; Rovner, DR; Srivastava, L, 1994) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 7.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment." | 7.66 | Control of malignant ascites with spironolactone. ( Greenway, B; Johnson, PJ; Williams, R, 1982) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 6.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "To elucidate the combined effects of fadrozole (nonsteroidal aromatase inhibitor) and tamoxifen, 11 postmenopausal patients with recurrent breast cancer were examined between October 1996 and June 1998." | 5.09 | [A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen]. ( Kimura, M; Nomura, Y; Ohashi, Y; Takashima, S; Toge, T; Tominaga, T, 2000) |
| "This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels." | 5.08 | Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995) |
| "Aminoglutethimide (Ag) is a potent aromatase-enzyme inhibitor used in the treatment of patients with breast cancer." | 5.07 | Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. ( Carella, MJ; Dimitrov, NV; Gossain, VV; Rovner, DR; Srivastava, L, 1994) |
| "Both medroxyprogesterone acetate (MPA) and megestrol acetate (MA) are effective in the treatment of metastatic breast cancer." | 5.05 | [Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies]. ( Blossey, HC; Emrich, D; Nagel, GA; Wander, HE, 1985) |
| "Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression." | 3.78 | ARIMIDEX: a new oral, once-a-day aromatase inhibitor. ( Demers, L; Dowsett, M; Dyroff, M; Plourde, PV; Webster, A; Yates, R, 1995) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 3.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment." | 3.66 | Control of malignant ascites with spironolactone. ( Greenway, B; Johnson, PJ; Williams, R, 1982) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 2.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "A subgroup of ERα-positive breast cancer is characterized by mosaic presence of a minor population of ERα-negative cancer cells expressing the basal cytokeratin-5 (CK5)." | 1.43 | Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. ( Girondo, MA; Goodman, CR; Hooke, JA; Hyslop, T; Kovatich, AJ; Liu, C; Mitchell, EP; Peck, AR; Rui, H; Sato, T; Shriver, CD; Yanac, AF; Yang, N, 2016) |
| "Aldosterone levels were significantly lowered below pretreatment values by the 1- and 2-mg twice daily doses." | 1.28 | Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. ( Coombes, RC; Davenport, J; Dowsett, M; Ford, HT; Gazet, JC; Hedley, A; Stein, RC, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (57.14) | 18.7374 |
| 1990's | 10 (23.81) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 2 (4.76) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Nounu, A | 1 |
| Kar, SP | 1 |
| Relton, CL | 1 |
| Richmond, RC | 1 |
| Goodman, CR | 1 |
| Sato, T | 1 |
| Peck, AR | 1 |
| Girondo, MA | 1 |
| Yang, N | 1 |
| Liu, C | 1 |
| Yanac, AF | 1 |
| Kovatich, AJ | 1 |
| Hooke, JA | 1 |
| Shriver, CD | 1 |
| Mitchell, EP | 1 |
| Hyslop, T | 1 |
| Rui, H | 1 |
| Rigiracciolo, DC | 1 |
| Scarpelli, A | 1 |
| Lappano, R | 1 |
| Pisano, A | 1 |
| Santolla, MF | 1 |
| Avino, S | 1 |
| De Marco, P | 1 |
| Bussolati, B | 1 |
| Maggiolini, M | 1 |
| De Francesco, EM | 1 |
| RIGHI, V | 1 |
| RIVERA, EM | 1 |
| ELIAS, JJ | 1 |
| BERN, HA | 1 |
| NAPALKOV, NP | 1 |
| PITELKA, DR | 1 |
| RIVADENEYRA, J | 1 |
| ABBES, M | 1 |
| CAMBON, P | 1 |
| PAILLAUD, F | 1 |
| Leo, JC | 1 |
| Guo, C | 1 |
| Woon, CT | 1 |
| Aw, SE | 1 |
| Lin, VC | 1 |
| Honda, M | 1 |
| Tsukada, T | 1 |
| Horiuchi, T | 1 |
| Tanaka, R | 1 |
| Yamaguchi, K | 1 |
| Obara, T | 1 |
| Miyakawa, H | 1 |
| Yamaji, T | 1 |
| Ishibashi, M | 1 |
| Halberg, F | 3 |
| Scaglia, HE | 1 |
| Koliren, L | 1 |
| Loruso, A | 1 |
| Zylbersztein, C | 1 |
| Ramos, G | 1 |
| Díaz, L | 1 |
| Soto, E | 1 |
| Sheeler, LR | 1 |
| Myers, JH | 1 |
| Eversman, JJ | 1 |
| Taylor, HC | 1 |
| Nelson, W | 1 |
| Bingham, C | 1 |
| Haus, E | 2 |
| Lakatua, DJ | 1 |
| Kawasaki, T | 1 |
| Worgul, TJ | 1 |
| Santen, RJ | 7 |
| Samojlik, E | 2 |
| Wells, SA | 3 |
| Hermida Domínguez, RC | 1 |
| del Pozo, F | 1 |
| Greenway, B | 1 |
| Johnson, PJ | 1 |
| Williams, R | 1 |
| Sebastian, A | 1 |
| Sutton, JM | 1 |
| Hulter, HN | 1 |
| Schambelan, M | 1 |
| Poler, SM | 1 |
| Plourde, PV | 1 |
| Dyroff, M | 1 |
| Dowsett, M | 2 |
| Demers, L | 1 |
| Yates, R | 1 |
| Webster, A | 1 |
| Carella, MJ | 1 |
| Dimitrov, NV | 1 |
| Gossain, VV | 1 |
| Srivastava, L | 1 |
| Rovner, DR | 1 |
| Demers, LM | 4 |
| Lipton, A | 6 |
| Harvey, HA | 3 |
| Hanagan, J | 2 |
| Mulagha, M | 2 |
| Kambic, KB | 1 |
| Grossberg, H | 1 |
| Brady, C | 1 |
| Bisagni, G | 1 |
| Cocconi, G | 1 |
| Scaglione, F | 1 |
| Fraschini, F | 1 |
| Pfister, C | 1 |
| Trunet, PF | 1 |
| Goss, PE | 1 |
| Clark, RM | 1 |
| Ambus, U | 1 |
| Weizel, HA | 1 |
| Wadden, NA | 1 |
| Crump, M | 1 |
| Walde, D | 1 |
| Tye, LM | 1 |
| De Coster, R | 1 |
| Bruynseels, J | 1 |
| Rosenberg Zand, RS | 1 |
| Jenkins, DJ | 1 |
| Diamandis, EP | 1 |
| Bello-Reuss, E | 1 |
| Ernest, S | 1 |
| Holland, OB | 1 |
| Hellmich, MR | 1 |
| Tominaga, T | 1 |
| Kimura, M | 1 |
| Toge, T | 1 |
| Takashima, S | 1 |
| Nomura, Y | 1 |
| Ohashi, Y | 1 |
| Blankvoort, BM | 1 |
| de Groene, EM | 1 |
| van Meeteren-Kreikamp, AP | 1 |
| Witkamp, RF | 1 |
| Rodenburg, RJ | 1 |
| Aarts, JM | 1 |
| Harvey, H | 3 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Honn, KV | 1 |
| Chavin, W | 1 |
| Braley, LM | 1 |
| Williams, GH | 1 |
| Haagensen, DE | 1 |
| Ruby, EJ | 1 |
| Dilley, WG | 1 |
| Lynch, J | 1 |
| Garber, JE | 1 |
| Henderson, IC | 1 |
| Navari, RM | 1 |
| Stein, RC | 1 |
| Davenport, J | 1 |
| Hedley, A | 1 |
| Ford, HT | 1 |
| Gazet, JC | 1 |
| Coombes, RC | 1 |
| Melby, JC | 2 |
| Wilson, TE | 1 |
| Wander, HE | 1 |
| Blossey, HC | 1 |
| Nagel, GA | 1 |
| Emrich, D | 1 |
| Matsuda, M | 1 |
| Plata, EJ | 1 |
| Aoki, T | 1 |
| Robertson, DD | 1 |
| Chu, EW | 1 |
| Gerwin, BI | 1 |
| Wellings, SR | 1 |
| Jentoft, VL | 1 |
| Grekin, RJ | 1 |
| Dale, SL | 1 |
| Givens, JR | 1 |
| Camacho, A | 1 |
| Patterson, P | 1 |
| Ceriani, RL | 1 |
| Contesso, GP | 1 |
| Nataf, BM | 1 |
| De Nicola, AF | 1 |
| Traikov, H | 1 |
| Birmingham, MK | 1 |
| Palmer, JD | 1 |
| Ruddick, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aldosterone and Breast Neoplasms
| Article | Year |
|---|---|
Quo vadis basic and clinical chronobiology: promise for health maintenance.
Topics: Adrenal Cortex; Alcoholism; Aldosterone; Biological Clocks; Blood Pressure; Breast Neoplasms; Cardio | 1983 |
Toward chronobiologic pattern discrimination of the risk of developing breast cancer and other diseases.
Topics: Adolescent; Adult; Age Factors; Aldosterone; Breast Neoplasms; Carbohydrate Metabolism; Circadian Rh | 1982 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
9 trials available for aldosterone and Breast Neoplasms
| Article | Year |
|---|---|
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Aged; Aldosterone; Aminoglutethimide; Breast Neoplasms | 1994 |
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Breast Neoplasms; Estradiol; Estrone; Fadrozole; Female; H | 1993 |
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cosynt | 1993 |
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
Topics: Adult; Aged; Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhi | 1996 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast | 1995 |
[A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen].
Topics: Aged; Aldosterone; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Breast Neoplasms; Female; Humans; Hydrocortis | 1985 |
Effect of aminoglutethimide and reserpine on the human pituitary-adrenal axis: remission of a case of Cushing's disease.
Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adult; Aldosterone; Aminoglutethimide; A | 1970 |
30 other studies available for aldosterone and Breast Neoplasms
| Article | Year |
|---|---|
Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Aldosterone; Androstenedione; Breast Neoplasms; Dehydroepiandro | 2022 |
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Topics: Aldosterone; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells.
Topics: Aldosterone; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Cell Movement; Cell Prol | 2016 |
[Study of adrenocortical function in patients subjected to mastectomy for breast cancer and treated by preoperative roentgenotherapy].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Breast Neoplasms; Humans; Mastectomy; Radiothe | 1962 |
TOXIC EFFECTS OF STERIOD HORMONES ON ORGAN CULTURES OF MOUSE MAMMARY TUMORS, WITH A COMMENT ON THE OCCURRENCE OF VIRAL INCLUSION BODIES.
Topics: Adenocarcinoma; Alcohols; Aldosterone; Animals; Breast Neoplasms; Cholesterol; Corticosterone; Desox | 1963 |
[INVESTIGATION OF THE BIOLOGICAL ACTIVITIES OF TRIAMCINOLONE DIACETATE IN PATIENTS WITH ADRENAL INSUFFICIENCY].
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenalectomy; Aldosterone; Blood; Blood Pressure; B | 1964 |
[APPLICATION OF ANTI-ALDOSTERONE DIURETICS TO THE TREATMENT OF LOCALIZED EDEMA OF THE EXTREMITIES IN CANCER PATIENTS].
Topics: Aldosterone; Breast Neoplasms; Diuretics; Edema; Extremities; Female; Humans; Mastectomy; Mineraloco | 1965 |
Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells.
Topics: Aldosterone; Breast Neoplasms; Cell Division; Cell Line, Tumor; Dexamethasone; Female; Focal Adhesio | 2004 |
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Adult; Aldosterone; Breast Neoplasms; DNA | 2004 |
Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Topics: Adult; Aged; Aldosterone; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dehydroepiandrosteron | 1984 |
Adrenal insufficiency secondary to carcinoma metastatic to the adrenal gland.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenal Insufficiency; Adrenocort | 1983 |
Rhythm-adjusted age effects in a concomitant study of twelve hormones in blood plasma of women.
Topics: Adolescent; Adult; Age Factors; Aldosterone; Analysis of Variance; Breast Neoplasms; Circadian Rhyth | 1980 |
How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Topics: Adrenalectomy; Aged; Aldosterone; Androgens; Androstenedione; Breast Neoplasms; Dehydroepiandrostero | 1982 |
Control of malignant ascites with spironolactone.
Topics: Abdominal Neoplasms; Aldosterone; Ascites; Breast Neoplasms; Female; Humans; Male; Renin; Sodium; Sp | 1982 |
Effect of mineralocorticoid replacement therapy on renal acid-base homeostasis in adrenalectomized patients.
Topics: Acid-Base Equilibrium; Adrenal Glands; Adrenalectomy; Aldosterone; Breast Neoplasms; Cushing Syndrom | 1980 |
Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2.
Topics: Aldosterone; Amino Acid Sequence; Antibodies, Monoclonal; Binding, Competitive; Biotin; Breast Neopl | 1999 |
Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells.
Topics: Adrenal Glands; Aldosterone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplas | 2000 |
Development of an androgen reporter gene assay (AR-LUX) utilizing a human cell line with an endogenously regulated androgen receptor.
Topics: Aldosterone; Androgens; Breast Neoplasms; Dexamethasone; Down-Regulation; Estradiol; Genes, Regulato | 2001 |
In vitro effects of theophylline and aminogluthetimide upon basal and ACTH induced cAMP levels and steroid output by the normal human adrenal gland.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Breast Neoplasms; Cycli | 1978 |
The effect of angiotensin II and saralasin on 18-hydroxy-11-deoxycorticosterone production by isolated human adrenal glomerulosa cells.
Topics: 18-Hydroxycorticosterone; 18-Hydroxydesoxycorticosterone; Adrenal Glands; Adrenalectomy; Aldosterone | 1979 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea | 1978 |
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Aromatase I | 1991 |
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Topics: Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Electro | 1990 |
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Topics: 18-Hydroxycorticosterone; Adrenal Cortex; Adrenocorticotropic Hormone; Aged; Aldosterone; Aromatase | 1990 |
Autotransplantation of the adrenal gland using microvascular anastomosis.
Topics: 17-Hydroxycorticosteroids; Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Aldost | 1987 |
An established cultured cell line (HBT-39) from human breast carcinoma.
Topics: Adult; Aldosterone; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Division; Cell L | 1973 |
Organ cultures of normal, dysplastic, hyperplastic, and neoplastic human mammary tissues.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adenofibroma; Aldosterone; Biopsy; Breast Disea | 1972 |
The role of 18-hydroxy-11-deoxycorticosterone as a precursor in human adrenal tissue in vitro.
Topics: Adrenal Glands; Adult; Aldosterone; Breast Neoplasms; Carbon Isotopes; Humans; Hydroxycorticosteroid | 1973 |
Hormone requirement for growth and differentiation of the human mammary gland in organ culture.
Topics: Adenofibroma; Aldosterone; Breast; Breast Neoplasms; Cell Differentiation; Culture Media; Epithelial | 1972 |
18-hydroxylation by human adrenal tissue in vitro.
Topics: Adrenal Glands; Aldosterone; Breast Neoplasms; Carbon Isotopes; Corticosterone; Crystallization; Des | 1970 |